503A vs 503B compounding is the split behind most US questions about compounded peptides. Two sections of the Federal Food, Drug, and Cosmetic Act set different rules for pharmacies and outsourcing facilities, including which bulk ingredients each may use. Sources were checked on November 17, 2026.
Quick answer: 503A pharmacies compound for individual patients on prescriptions, overseen mainly by state boards of pharmacy. 503B outsourcing facilities register with FDA, follow manufacturing standards and are inspected by FDA. A 503A compounder may use a bulk substance if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list. A 503B facility may use one only if it is on the 503B bulks list or the drug is on FDA’s shortage list. Either way, compounded drugs are not FDA-approved.
This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.
What is a 503A pharmacy?
Section 503A (21 U.S.C. 353a) covers drugs “compounded for an identified individual patient based on the receipt of a valid prescription order.” FDA describes the compounder as a licensed pharmacist in a state-licensed pharmacy or federal facility, or a physician. These compounders are not subject to current good manufacturing practice (CGMP) requirements, and state boards of pharmacy have primary day-to-day oversight (FDA, 2025).
When all of 503A’s conditions are met, the drug is exempt from the CGMP, adequate-directions and FDA approval requirements. When any condition is not met, those exemptions do not apply.
What is a 503B outsourcing facility?
FDA describes outsourcing facilities as “a category of compounders established in 2013 by the Drug Quality and Security Act.” They register with FDA, are subject to CGMP requirements and are inspected by FDA on a risk-based schedule (FDA, 2025).
Section 503B (21 U.S.C. 353b) requires that drugs be compounded “by or under the direct supervision of a licensed pharmacist.” An outsourcing facility is a facility “at one geographic location or address” engaged in sterile compounding. It “is not required to be a licensed pharmacy” and “may or may not obtain prescriptions for identified individual patients.” Its drugs are exempt from the approval, adequate-directions and certain supply-chain tracing requirements, but not from CGMP. Table 1 compares the two.
503A pharmacies and 503B outsourcing facilities compared
| Feature | 503A | 503B |
|---|---|---|
| Who compounds | Licensed pharmacist in a state-licensed pharmacy or federal facility, or a physician | Registered outsourcing facility, under a licensed pharmacist’s direct supervision |
| Prescriptions | For an identified individual patient, on a valid prescription | May or may not obtain patient prescriptions |
| Main oversight | State boards of pharmacy | FDA registration and risk-based inspection |
| CGMP | Not subject to CGMP | Subject to CGMP |
| Bulk drug substances | USP or NF monograph, component of an approved drug, or on the 503A bulks list | On the 503B bulks list (clinical need), or the drug is on FDA’s shortage list |
| Copies of approved drugs | Not “regularly or in inordinate amounts” | Not allowed, unless the approved drug is on the shortage list |
| FDA approval of the compounded drug | None | None |
How are bulk drug substances listed for 503A?
The statute sets three routes in order. A bulk drug substance must comply with an applicable USP or NF monograph. If none exists, it must be a component of an FDA-approved drug. If it is neither, it must appear on a list FDA develops through regulations, called the 503A bulks list (FDA, 2026). Our article on peptides and 503A compounding has more background.
How are bulk drug substances listed for 503B?
Under section 503B, a bulk drug substance must appear on a list of substances “for which there is a clinical need,” or the drug compounded from it must appear on FDA’s drug shortage list “at the time of compounding, distribution, and dispensing.” Listing requires a Federal Register proposal and at least 60 days for comment.
FDA’s page lists five substances: diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester and trichloroacetic acid, each with use limits. FDA decided not to include more than 20 others, among them vasopressin (FDA, 2024).
What are FDA’s categories for nominated substances?
While FDA reviews nominations, its interim policies sort each nominated substance into one of three categories, for both 503A and 503B:
- Category 1: under evaluation. FDA does not intend to take action against compounders using these substances if the guidance conditions are met.
- Category 2: FDA has identified “significant safety risks relating to the use of these substances in compounding.”
- Category 3: nominated with “insufficient supporting information for FDA to evaluate them.”
Category 1 is not approval or a place on a bulks list; it reflects an interim enforcement policy (FDA, 2025). FDA also keeps a separate table of substances whose nominations were withdrawn.
How do drug shortage rules work?
Under 503A, a pharmacy may not compound “regularly or in inordinate amounts” drugs that are essentially copies of a commercially available drug product. FDA does not treat a drug on its shortage list as commercially available, so that limit does not apply while the shortage lasts (FDA, 2025). In its April 2026 GLP-1 policy, FDA said it does not intend to act against a 503A compounder that fills four or fewer prescriptions of such a copy in a calendar month (FDA, 2026).
Under 503B, a facility may compound from a bulk substance when the drug is on the shortage list, and the ban on copying an approved drug does not apply to a drug on that list. When a drug comes off the list, FDA says it may act if a facility keeps filling new orders, or fills existing orders more than 60 days after removal.
How does this apply to peptides?
FDA names peptides at each stage of this system:
- Semaglutide and tirzepatide: FDA declared the shortages resolved in February 2025 and December 2024. On April 1, 2026, FDA wrote: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding “no clinical need” (FDA, 2026). The comment period was extended to July 30, 2026 (91 FR 38719). We found no final decision.
- Category 2 peptides: kisspeptin-10 for 503A, and GHRP-2, GHRP-6 and ipamorelin acetate for 503B (FDA, 2026).
- Withdrawn nominations: FDA lists BPC-157, AOD-9604, CJC-1295, KPV, melanotan II, MOTS-c, TB-500 and thymosin alpha-1, among others.
- Advisory committee review: at the July 23, 2026 meeting, FDA staff proposed that BPC-157, KPV, TB-500 and MOTS-c “NOT be included on the 503A Bulks List” (FDA, 2026). The committee advises; FDA decides. We found no final decision.
- 503A category 1: includes GHK-Cu for non-injectable routes, glutathione and vasoactive intestinal peptide. FDA plans to consult its advisory committee on GHK-Cu before the end of February 2027 (FDA, 2026).
Our pages on compounded semaglutide and compounded tirzepatide cover those two cases in detail.
What is the October 2026 HHS draft peptide policy?
On October 30, 2026, the HHS Office of the Secretary published a notice of availability for a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 FR 68526). It covers 503A compounding only, not 503B. The notice says HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A.” It applies while the 503A bulks list “is developed through rulemaking.”
Three limits matter. The notice calls it a draft, interim policy that “is not binding on HHS or the public.” HHS may revisit it if “a safety signal or product quality issue arises.” And the peptides are not named in the Federal Register text; they are in Appendix A of the policy document on the HHS website. Comments were open for two weeks under docket HHS-OASH-2026-0496, and as of November 17, 2026 we found no final version. FDA’s future rulemakings “may propose adding some or all of these peptides to the 503A bulks list.” Enforcement discretion is neither a place on that list nor FDA approval.
Frequently asked questions about 503A and 503B compounding
Is a compounded drug FDA-approved?
No. FDA states that compounded drugs are not FDA-approved, under either section.
Does a 503B facility need a prescription for each patient?
The statute says an outsourcing facility “may or may not obtain prescriptions for identified individual patients.” A 503A pharmacy compounds for an identified patient on a valid prescription.
Is Vitrapep a compounding pharmacy?
No. Vitrapep is not a 503A compounding pharmacy or a 503B outsourcing facility. We sell research peptides for laboratory research use only, not for human or veterinary use.
What to know now
- 503A: patient prescriptions, state board oversight; bulks need a monograph, an approved-drug component or the 503A list.
- 503B: FDA registration and CGMP; bulks need the clinical-need list or the shortage list.
- Categories: 1 under evaluation, 2 significant safety risks, 3 insufficient support.
- Peptides: semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list.
- HHS draft policy: October 30, 2026; covers peptides in its Appendix A; not binding, not final.
What we’re watching
Whether HHS finalizes, changes or withdraws its draft peptide policy. FDA’s final decision on semaglutide, tirzepatide and liraglutide for the 503B bulks list. Any FDA decision on BPC-157, KPV, TB-500 and MOTS-c. And the GHK-Cu advisory committee consultation planned before the end of February 2027.